Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658368 | 0.94 | ADRA1D (0.60) | NPSR1MAPTTSHRGFERHTR1A | |
| SCHEMBL5655862 | 0.92 | NPSR1 (0.59) | NPSR1MAPTTSHRGFERKMT2A | |
| SCHEMBL5656079 | 0.92 | NPC1 (0.64) | MAPTGFERHTR1AKMT2AMEN1 | |
| SCHEMBL5656799 | 0.91 | NPSR1 (0.58) | NPSR1MAPTTSHRKMT2AMEN1 | |
| SCHEMBL5655791 | 0.91 | NPSR1 (0.61) | NPSR1MAPTTSHRGFERKMT2A | |
| SCHEMBL5657928 | 0.90 | MAPT (0.72) | NPSR1MAPTTSHRKMT2AMEN1 | |
| SCHEMBL5658367 | 0.89 | HTR1A (0.61) | NPSR1MAPTGFERHTR1AKMT2A | |
| SCHEMBL5654228 | 0.88 | NPSR1 (0.55) | NPSR1MAPTTSHRGFERHTR1A | |
| SCHEMBL5657864 | 0.86 | L3MBTL1 (0.59) | NPSR1MAPTTSHRGFERHTR1A | |
| SCHEMBL5656389 | 0.85 | ADRA1D (0.65) | NPSR1MAPTHTR1AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | NPSR1 37/4885MAPT 3644/4885TSHR 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.